These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 32573916)

  • 1. An indirect high iodine (
    Al-Shakhrah IA
    J Appl Clin Med Phys; 2020 Jul; 21(7):173-180. PubMed ID: 32573916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determination and Comparison of Radiation Absorbed dose to the Blood, by Applying Different Techniques, for Patients, Suffering from Differentiated Thyroid Cancer.
    Al-Shakhrah IA
    Indian J Nucl Med; 2020; 35(1):28-35. PubMed ID: 31949366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Prospective Study to Evaluate the Possible Role of Cholecalciferol Supplementation on Autoimmunity in Hashimoto's Thyroiditis.
    Bhakat B; Pal J; Das S; Charaborty SK; SircarMedical NR; Kolkata ; RGKar ; NorthBengal ; Siliguri
    J Assoc Physicians India; 2023 Jan; 71(1):1. PubMed ID: 37116030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimation of Second Primary Cancer Risk After Treatment with Radioactive Iodine for Differentiated Thyroid Carcinoma.
    Corrêa NL; de Sá LV; de Mello RC
    Thyroid; 2017 Feb; 27(2):261-270. PubMed ID: 27762670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radioiodine lobar ablation as an alternative to completion thyroidectomy in patients with differentiated thyroid cancer.
    Bal CS; Kumar A; Pant GS
    Nucl Med Commun; 2003 Feb; 24(2):203-8. PubMed ID: 12548045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calculation of Blood Dose in Patients Treated With 131I Using MIRD, Imaging, and Blood Sampling Methods.
    Piruzan E; Haghighatafshar M; Faghihi R; Entezarmahdi SM
    Medicine (Baltimore); 2016 Mar; 95(11):e3154. PubMed ID: 26986171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone marrow dosimetry and safety of high 131I activities given after recombinant human thyroid-stimulating hormone to treat metastatic differentiated thyroid cancer.
    de Keizer B; Hoekstra A; Konijnenberg MW; de Vos F; Lambert B; van Rijk PP; Lips CJ; de Klerk JM
    J Nucl Med; 2004 Sep; 45(9):1549-54. PubMed ID: 15347723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erratum: Eyestalk Ablation to Increase Ovarian Maturation in Mud Crabs.
    J Vis Exp; 2023 May; (195):. PubMed ID: 37235796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo formation of gamma-H2AX and 53BP1 DNA repair foci in blood cells after radioiodine therapy of differentiated thyroid cancer.
    Lassmann M; Hänscheid H; Gassen D; Biko J; Meineke V; Reiners C; Scherthan H
    J Nucl Med; 2010 Aug; 51(8):1318-25. PubMed ID: 20660387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Whole-remnant and maximum-voxel SPECT/CT dosimetry in
    Mínguez P; Flux G; Genollá J; Delgado A; Rodeño E; Sjögreen Gleisner K
    Med Phys; 2016 Oct; 43(10):5279-5287. PubMed ID: 28105713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiation dose to the testes after 131I therapy for ablation of postsurgical thyroid remnants in patients with differentiated thyroid cancer.
    Ceccarelli C; Battisti P; Gasperi M; Fantuzzi E; Pacini F; Gualdrini G; Pierantoni MC; Luciani A; Djokich D; Pinchera A
    J Nucl Med; 1999 Oct; 40(10):1716-21. PubMed ID: 10520714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimation of blood and bone marrow doses of thyroid carcinoma patients treated with
    Albornoz-Castañeda F; Díaz-Londoño G; García-Arencibia M; Sirandoni-Riquelme G
    J Radiol Prot; 2018 Dec; 38(4):1359-1370. PubMed ID: 30226212
    [No Abstract]   [Full Text] [Related]  

  • 13. Iodine biokinetics and radioiodine exposure after recombinant human thyrotropin-assisted remnant ablation in comparison with thyroid hormone withdrawal.
    Taïeb D; Sebag F; Farman-Ara B; Portal T; Baumstarck-Barrau K; Fortanier C; Bourrelly M; Mancini J; De Micco C; Auquier P; Conte-Devolx B; Henry JF; Mundler O
    J Clin Endocrinol Metab; 2010 Jul; 95(7):3283-90. PubMed ID: 20392868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dosimetry in differentiated thyroid carcinoma (12-1402R).
    Minguez P; Genolla J; Celeiro JJ; Fombellida JC
    Med Phys; 2013 Jan; 40(1):012502. PubMed ID: 23298113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A dose-effect correlation for radioiodine ablation in differentiated thyroid cancer.
    Flux GD; Haq M; Chittenden SJ; Buckley S; Hindorf C; Newbold K; Harmer CL
    Eur J Nucl Med Mol Imaging; 2010 Feb; 37(2):270-5. PubMed ID: 19760413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of the radioiodine whole-body retention at 48 hours for modifying empiric activity of 131-iodine for the treatment of metastatic well-differentiated thyroid carcinoma.
    Van Nostrand D; Atkins F; Moreau S; Aiken M; Kulkarni K; Wu JS; Burman KD; Wartofsky L
    Thyroid; 2009 Oct; 19(10):1093-8. PubMed ID: 19732012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre-therapeutic blood dosimetry in patients with differentiated thyroid carcinoma using 124-iodine: predicted blood doses correlate with changes in blood cell counts after radioiodine therapy and depend on modes of TSH stimulation and number of preceding radioiodine therapies.
    Hartung-Knemeyer V; Nagarajah J; Jentzen W; Ruhlmann M; Freudenberg LS; Stahl AR; Bockisch A; Rosenbaum-Krumme SJ
    Ann Nucl Med; 2012 Nov; 26(9):723-9. PubMed ID: 22802008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant human thyrotropin (rhTSH) aided radioiodine treatment for residual or metastatic differentiated thyroid cancer.
    Ma C; Xie J; Liu W; Wang G; Zuo S; Wang X; Wu F
    Cochrane Database Syst Rev; 2010 Nov; 2010(11):CD008302. PubMed ID: 21069705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiation dose rates from patients receiving iodine-131 therapy for carcinoma of the thyroid.
    Barrington SF; Kettle AG; O'Doherty MJ; Wells CP; Somer EJ; Coakley AJ
    Eur J Nucl Med; 1996 Feb; 23(2):123-30. PubMed ID: 8925845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Red marrow and blood dosimetry in (131)I treatment of metastatic thyroid carcinoma: pre-treatment versus in-therapy results.
    Giostra A; Richetta E; Pasquino M; Miranti A; Cutaia C; Brusasco G; Pellerito RE; Stasi M
    Phys Med Biol; 2016 Jun; 61(11):4316-26. PubMed ID: 27200493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.